SHOWNOTES
This week on Telltales, the team digs into the cash flow realities behind energy markets, AI-driven software disruption, and fast-moving healthcare headlines. Plus, they connect the dots between government finances, rates, and the incentives shaping corporate behavior.
[00:00] Welcome to Telltales + Cash Flow Memo The crew tees up a fast tour through energy, technology, and healthcare using this week’s memo and exhibits.
[00:19] Disclaimer Investing discussion for informational purposes only—do your own work.
[00:35] Oil demand growth slows, supply stays strong Why global demand growth looks softer (China maturity, EV adoption) and what that implies for WTI absent geopolitical risk.
[02:40] Natural gas: “too much production” and power demand flat The group discusses why gas demand in power isn’t accelerating and how policy/regulatory dynamics may be affecting coal retirements.
[03:39] Exhibit A: Tariffs, revenues, and the bond market A look at shifting U.S. revenue lines, tariff uncertainty/refunds, and why the 10-year yield matters for housing affordability.
[07:06] SaaS disruption: opportunity or value trap? Salesforce, ServiceNow, and Snowflake sell off as investors debate “build vs buy” software in an AI world—and what that means for durable cash flow.
[10:00] Switching costs, SLAs, and the real value of software vendors Why uptime, support, and accountability still matter—and why the endpoint may be “more software,” not less.
[13:40] Meta’s AMD GPU deal and the Taiwan Semi choke point A breakdown of buyer power in AI chips, why capacity allocation matters, and how warrant structures reshape incentives.
[17:16] Streaming and platforms: Disney, Netflix, Meta, Spotify Comparing balance sheets, valuation moves, and how AI could (or won’t) improve these business models.
[21:18] Healthcare: GLP-1 price war dynamics What happens when insurance isn’t the payer, Novo vs Lilly pricing pressure, and why safety may be the more important “race” than speed of weight loss.
[22:33] UnitedHealth, PBMs, and regulatory whack-a-mole The team discusses PBM vulnerability, potential margin shifts, and why fraud enforcement/data transparency could change incentives.
[25:03] Longevity: Yamanaka factors and first-in-human study A look at Life Biosciences, organ “reprogramming” research, and how AI may accelerate earlier-stage discovery.
[26:07] Hims & Hers vs Novo Nordisk: compounding, patents, and enforcement How shortages opened the door, where the envelope got pushed too far, and why IP protection underpins pharma innovation.
[28:28] Cancer vaccines: additive, not replacing standard of care Why the highest-probability outcome is vaccines reducing recurrence post-treatment—and what that means for future cost and care intensity.
[31:05] Grail’s early cancer detection study: promising theory, tough economics The study design trade-offs, funding constraints, and whether improved technology could revive the approach.
[33:16] Wrap-up The crew signs off and previews next week—download the Cash Flow Memo and follow along with the exhibits for deeper context.
If you found this helpful, like, subscribe, and share the episode—and grab the Cash Flow Memo so you can track the numbers alongside the discussion.
This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
